The Surprising FDA View That Sent Moderna Stock Flying
Moderna stock prices increased following positive feedback from the FDA regarding the company's mRNA influenza vaccine candidate.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has released a review appearing to align with Moderna's development of an mRNA-based influenza vaccine. This development coincides with reports that the technology expands B cell response breadth and provides protection against a diverse range of influenza strains.
Coverage from Fierce Biotech, BioSpace, and Investor's Business Daily emphasizes the current alignment between regulators and the company. Nature and Medical Xpress provide the underlying scientific context regarding the vaccine's ability to trigger broader human immune responses.
Market participants are monitoring the upcoming advisory committee meeting. Coverage does not yet specify the exact date of the adcomm grilling or the specific metrics of the stock price movement.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
Why did Moderna stock rise?
Investor's Business Daily reports the increase followed a favorable review from the FDA concerning the company's mRNA flu vaccine.
What does the science say about the vaccine?
According to Nature and Medical Xpress, the vaccine has shown potential to expand the breadth of human B cell responses and offer protection against diverse influenza strains.
What is the next step for the vaccine?
Fierce Biotech and BioSpace indicate that an advisory committee review is the next significant event.
Coverage (5)
- Amenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling Fierce Biotech · 3h ago
- mRNA-based influenza vaccine expands the B cell response breadth in humans Nature · 3h ago
- mRNA flu vaccine offers immune protection against diverse strains Medical Xpress · 3h ago
- FDA, Moderna appear aligned on mRNA flu shot heading into adcomm BioSpace · 3h ago
- The Surprising FDA View That Sent Moderna Stock Flying Investor's Business Daily · 3h ago
Topics
Related trends
Baby formula recalled after infant botulism in WA
Nara Organics has issued a recall for all lots of its powdered infant formula following reports of infant botulism cases across three states.
Alfredo sauce recalled over potential salmonella contamination
Alfredo sauce sold across 41 states faces a high-risk recall due to potential salmonella contamination.
4 things to know about the new sunscreen ingredient the FDA approved
The FDA has authorized the use of bemotrizinol, the first new sunscreen ingredient approved for the U.S. market in two decades.
Scientists Race to Test Treatments as Ebola Outbreak Widens
Global research efforts accelerate as scientists scramble to test new vaccines and treatments in response to a widening Ebola outbreak.
Menopause hormone therapy: Demand rises but training gaps remain
Public interest in menopause hormone therapy is surging, shifting medical discourse and highlighting critical gaps in provider training.
FDA’s e-cigarette authorization: Fruity vapes not significantly better than tobacco ones
FDA’s approval of flavored vapes sparks debate over public health vs. political influence